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Interdisciplinary model of care (RADICALS) for early detection and management
of chronic obstructive pulmonary disease (COPD) in Australian primary care:
study protocol for a cluster randomised controlled trial
Abstract
Introduction Up to half of all smokers develop clinically significant chronic obstructive pulmonary disease
(COPD). Gaps exist in the implementation and uptake of evidencebased guidelines for managing COPD in
primary care. We describe the methodology of a cluster randomised controlled trial (cRCT) evaluating the
efficacy and costeffectiveness of an interdisciplinary model of care aimed at reducing the burden of
smoking and COPD in Australian primary care settings. Methods and analysis A cRCT is being undertaken
to evaluate an interdisciplinary model of care (RADICALS - Review of Airway Dysfunction and
Interdisciplinary Community-based care of Adult Long-term Smokers). General practice clinics across
Melbourne, Australia, are identified and randomised to the intervention group (RADICALS) or usual care.
Patients who are current or ex-smokers, of at least 10 pack years, including those with an existing
diagnosis of COPD, are being recruited to identify 280 participants with a spirometry-confirmed diagnosis
of COPD. Handheld lung function devices are being used to facilitate case-finding. RADICALS includes
individualised smoking cessation support, home-based pulmonary rehabilitation and home medicines
review. Patients at control group sites receive usual care and Quitline referral, as appropriate. Follow-ups
occur at 6 and 12months from baseline to assess changes in quality of life, abstinence rates, health
resource utilisation, symptom severity and lung function. The primary outcome is change in St George's
Respiratory Questionnaire score of patients with COPD at 6months from baseline. Ethics and
dissemination This project has been approved by the Monash University Human Research Ethics
Committee and La Trobe University Human Ethics Committee (CF14/1018 - 2014000433). Results of the
study will be disseminated in peer-reviewed journals and research conferences. If the intervention is
successful, the RADICALS programme could potentially be integrated into general practices across
Australia and sustained over time.
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ABSTRACT
Introduction Up to half of all smokers develop clinically
significant chronic obstructive pulmonary disease (COPD).
Gaps exist in the implementation and uptake of evidencebased guidelines for managing COPD in primary care.
We describe the methodology of a cluster randomised
controlled trial (cRCT) evaluating the efficacy and costeffectiveness of an interdisciplinary model of care aimed
at reducing the burden of smoking and COPD in Australian
primary care settings.
Methods and analysis A cRCT is being undertaken to
evaluate an interdisciplinary model of care (RADICALS
— Review of Airway Dysfunction and Interdisciplinary
Community-based care of Adult Long-term Smokers).
General practice clinics across Melbourne, Australia,
are identified and randomised to the intervention group
(RADICALS) or usual care. Patients who are current or
ex-smokers, of at least 10 pack years, including those
with an existing diagnosis of COPD, are being recruited
to identify 280 participants with a spirometry-confirmed
diagnosis of COPD. Handheld lung function devices are
being used to facilitate case-finding. RADICALS includes
individualised smoking cessation support, home-based
pulmonary rehabilitation and home medicines review.
Patients at control group sites receive usual care and
Quitline referral, as appropriate. Follow-ups occur at 6 and
12 months from baseline to assess changes in quality of
life, abstinence rates, health resource utilisation, symptom
severity and lung function. The primary outcome is change
in St George’s Respiratory Questionnaire score of patients
with COPD at 6 months from baseline.
Ethics and dissemination This project has been
approved by the Monash University Human Research
Ethics Committee and La Trobe University Human Ethics
Committee (CF14/1018 – 2014000433). Results of the
study will be disseminated in peer-reviewed journals and
research conferences. If the intervention is successful, the
RADICALS programme could potentially be integrated into
general practices across Australia and sustained over time.

Strengths and limitations of this study
►► A large implementation trial in primary care involving

current smokers, ex-smokers and patients with an
existing diagnosis of chronic obstructive pulmonary
disease.
►► Cluster randomisation of general practices to
minimise the risk of contamination, and blinded
outcome assessment.
►► Open-labelled trial; participants and health
professionals are not blinded, with a potential for
Hawthorne effect.

Trial registration number ACTRN12614001155684; Preresults.

Introduction
Chronic
obstructive
pulmonary
disease (COPD) (COPD) is a major public
health problem. Symptoms and complications of the condition can greatly affect
patients’ ability to undertake daily activities,
impair quality of life and result in extensive use of health services. According to the
World Health Organisation (WHO), COPD
is the fourth leading cause of death and is
projected to be the third leading cause of
death by 2030 (potentially contributing to
8.6% of deaths worldwide).1 In Australia,
the overall prevalence of moderate to severe
COPD in adults aged 40 years and over is
7.5% (95% CI 5.7% to 9.4%).2 3 The prevalence increases to 29.2% (95% CI 18.1% to
40.2%) among those aged 75 years and over.3
In 2012, 4% of all deaths among Australians
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aged 55 years and over was attributed to COPD.4 The rate
of hospitalisation for COPD among those aged 55 and
over was 1052 per 100 000 population.5 It was estimated
that the rate of COPD management in Australian general
practices during 2013–2014 was 1.0 (95% CI 0.9 to 1.1)
per 100 encounters, an increase from 0.8 (95% CI 0.7 to
0.9) in 2004–2005.6
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) defines COPD as ‘a common preventable
and treatable disease, [which] is characterised by persistent
airflow limitation that is usually progressive and associated with
an enhanced chronic inflammatory response in the airways and
the lung to noxious particles or gases’.7 The greatest and most
preventable risk factor for the development of COPD
is tobacco smoking, with up to 50% smokers eventually
developing clinically significant COPD.8
Numerous guidelines for the diagnosis, management
and prevention of COPD have been published. The
Lung Foundation Australia (LFA) and the Thoracic
Society of Australia and New Zealand have summarised
current evidence and developed a set of guidelines for
the optimal management of people with COPD, known as
the COPD-X Plan.9 The COPD-X guidelines recommend
key components of COPD management, including lung
function testing to confirm diagnosis, optimising both
pharmacological and non-pharmacological therapies
including pulmonary rehabilitation, smoking cessation
support, vaccinations, appropriate oxygen therapy, development of support networks and self-management plans,
and appropriate management of exacerbations.9 More
recently, a concise guide of the COPD-X Plan has been
published and distributed for use in primary care.10
Despite numerous guidelines for COPD management,
studies conducted in other countries have revealed gaps
in health practitioner knowledge of and adherence to
these guidelines.11 Audits of primary care professionals’
adherence to COPD guidelines in Australia and overseas
have consistently shown deviations from optimal pharmacological treatment, lack of referrals to pulmonary rehabilitation and underutilisation of spirometry in COPD
diagnosis.12–21
Underdiagnosis and misdiagnosis of COPD in the
Australian population are common.2 22–24 This may be
due to the general underutilisation of spirometry in both
hospital and primary care settings.22 24–27 It is estimated
that at least 600 000 Australians have moderate to severe
COPD of which they are unaware and therefore not
receiving appropriate treatment.22 28 29 There is a need for
greater awareness of COPD among primary care health
providers to promote earlier diagnosis and more timely
initiation of appropriate treatments.22
Optimal pharmacological treatment is important in
controlling the symptoms of COPD and preventing
exacerbations. Deviations from recommended pharmacological treatments have been identified, especially in
relation to use of corticosteroids (inhaled and oral) and
antibiotics.21 30 In recent years, multiple new therapeutic
agents for managing COPD have been introduced onto
2

the Australian market. These agents include new longacting muscarinic antagonists (LAMAs), inhaled corticosteroid/long-acting beta agonist (LABA) combinations
and LAMA/LABA combinations. New inhaler devices
have also been developed for the delivery of these novel
agents, creating additional challenges for health professionals and patients alike.
Pulmonary rehabilitation is a key non-pharmacological
component in the management of COPD. Improvements
in the quality of life of patients with COPD following
pulmonary rehabilitation can be seen in the Chronic
Respiratory Disease Questionnaire scores in areas of
dyspnoea, fatigue, mastery and emotional function, along
with an enhancement in patients’ sense of control over
their condition.31 Despite the compelling evidence of its
benefits, access to pulmonary rehabilitation programmes
remains limited in Australia. It is estimated that only
5%–10% of patients with moderate to severe COPD use
pulmonary rehabilitation services in Australia.32 Similarly low rates of pulmonary rehabilitation uptake are
reported across the developed world.33 34 A combination
of programme-related factors and barriers at both the
patient and referrer level contributes to low access rates.
Poor knowledge of the benefits of pulmonary rehabilitation in the management of COPD, limited knowledge of
the referral process,32 35 inconvenience of travel to hospital-based programmes, concerns from culturally and
linguistically diverse patients, and the lack of perceived
benefit of pulmonary rehabilitation have been reported
to affect the uptake and completion of these programmes
by eligible patients.36–38
Interdisciplinary practice-based interventions have
shown to lead to positive changes in healthcare, including
improvements in patient care.39 An interdisciplinary
approach could potentially benefit the management of
patients with COPD. Many different healthcare professionals are involved in the crucial components of COPD
management, including smoking cessation support,
pharmacotherapy, self-management education and exercise training. Effects of an interdisciplinary approach
on COPD patient outcomes have been analysed. Studies
have demonstrated the potential benefits of an interdisciplinary approach on patient quality of life, symptom
control, exercise tolerance and hospital episodes.40 41
Other studies have shown improvements in the level of
follow-up, self-reported daily activities, pulmonary rehabilitation attendance and disease knowledge among
patients with COPD.24 42
Primary care services in Australia are predominantly delivered by the nation’s 22 000 general practitioners (GPs), nearly all of whom working in privately
owned general practice settings. Primary healthcare
providers also include nurses (general practice nurses,
community nurses and nurse practitioners), allied health
professionals, midwives, pharmacists, dentists and Aboriginal health workers. The primary healthcare services
include health promotion, prevention and screening,
early intervention, treatment and management.43 Clinical
Liang J, et al. BMJ Open 2017;7:e016985. doi:10.1136/bmjopen-2017-016985
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care provided within general practice is predominantly
reimbursed by fee-for-service payments (through the
Australian Federal Government’s Medical Benefits
Scheme (MBS)), although GPs are also able to attract
copayments for their services. The MBS in Australia allows
GPs to claim for services surrounding chronic disease
management. These include GP preparation of chronic
disease management plans, plans for ongoing treatment
by a multidisciplinary team (GP along with at least two
other health professionals) and for pharmacist-conducted home medication review (HMR) services.44
Currently, delivery of pulmonary rehabilitation
programmes and HMRs is on a GP referral basis. Remuneration is available to pharmacists for HMR services
(home visit and generation of a report of findings and
recommendations to the referring practitioner) through
the MBS. However, there is no remuneration pathway for
private physiotherapists providing pulmonary rehabilitation programmes in the community. A formal model of
care bringing together services provided by various health
professionals for the management of patients with COPD
is lacking. An interdisciplinary model of care involving
GPs and other practice staff, pharmacists and physiotherapists has not been evaluated in the Australian primary
care setting.
Aims and objectives
The primary aim of this study is to determine the efficacy,
for patients with COPD, of an interdisciplinary model of
care (RADICALS — Review of Airway Dysfunction and
Interdisciplinary Community-based care of Adult Longterm Smokers) compared with usual care on health-related quality of life (HRQoL), measured at 6 months
using the St George’s Respiratory Questionnaire (SGRQ).
The secondary objectives are to determine the proportion of smokers with spirometry-confirmed COPD and
evaluate the efficacy of RADICALS compared with usual
care on smoking abstinence, nicotine dependence, lung
function, symptom severity, health resource utilisation
(unplanned GP visits, hospitalisations and emergency
department presentations), anxiety and depression
scores, and medication adherence at 6 and 12 months.
If the interdisciplinary model is shown to be effective, an
economic evaluation will be conducted to compare the
costs and benefits of the model with usual care.

Methods
This is a cluster randomised controlled trial in primary
care clinics across Melbourne, Australia. Eligible primary
care clinics that consent are randomised to either intervention (interdisciplinary care group=ICG) or control
(usual care group=UCG). Participants are recruited from
each clinic and receive the intervention or usual care
depending on the allocation of the clinic. Each participant is screened for eligibility at baseline and completes
follow-up interviews at 6 and 12 months from baseline.
Liang J, et al. BMJ Open 2017;7:e016985. doi:10.1136/bmjopen-2017-016985

The RADICALS intervention is delivered to participants
from ICG clinics (see figure 1).
Practice recruitment
Eligible practices are identified through advertisements
and consultation with the Eastern Melbourne PHN and
key informants. Direct approaches to clinics (telephone
contact, direct emails with study information, brief
presentations at GP continuing professional development
events, door knocking and so on) may also be employed.
The practice is formally enrolled into the study upon
receipt of a signed practice agreement form.
Inclusion and exclusion criteria
Group or solo primary care practices with at least 1000
patients in their databases are eligible for inclusion in the
trial. Primary care practices must also be willing to accommodate research staff at the practice or have personnel at
the practice willing to undertake training and dedicate
time to specific tasks of the research project.
Randomisation: allocation, concealment and sequence generation
Primary care clinics are block-randomised, using block
sizes of four and six, into ICG or UCG using a web-based
randomisation program managed by an independent
agency. Research assistants (RAs) and practice staff on
site are notified of the allocation of their clinic. Cluster
randomisation of clinics minimises the risk of contamination across intervention and control groups when participants from the same clinic are managed by the same GPs
and/or clinic staff. However, observed outcomes among
participants sampled within the same clinic may still be
more similar than outcomes observed in participants
sampled from different clinics. The sample size has been
increased depending on the size of clinics randomised
and the degree of similarity of outcomes among members
of the same clinic, measured in terms of the intracluster
or intraclass correlation coefficient.45
Participant recruitment
Eligible patient participants are identified through
searching of the practice clinical database by an RA
employed at each site or trained practice staff. Practice
staff are also informed of the study and asked to refer
patients who meet eligibility criteria. Letters with an
Expression of Interest form are sent from the practice
to eligible patients formally inviting them to take part
in the study. Those interested in the study are asked to
return the completed form in a reply-paid envelope.
Non-respondents are sent up to two reminders. Informed
consent is sought after provision of study information,
a plain language statement and opportunities for any
questions. A toll-free number is set up and is available to
potential participants for this purpose. Baseline data are
collected after written informed consent is obtained.
Inclusion and exclusion criteria
Current or ex-smokers with a history of at least 10 pack
years of smoking, aged 40 years or older, including those
3

Downloaded from http://bmjopen.bmj.com/ on October 29, 2017 - Published by group.bmj.com

Open Access

Figure 1

RADICALS study flow diagram. COPD, chronic obstructive pulmonary disease; GP, general practitioner.

with an existing diagnosis of COPD, who had two or
more visits to the practice in the previous 12 months, are
included. Two or more visits will indicate patient engagement with the practice. Those with no history of smoking
are eligible only if they have spirometry-confirmed COPD.
Exclusion criteria include patients with a terminal
illness (anticipated survival <12 months), those unable
to provide informed consent (eg, cognitive impairment),
those with pre-existing interstitial lung disease, unstable
cardiovascular status, comorbidities preventing participation in an exercise training programme or contraindications to spirometry (including abdominal/thoracic/
neurosurgery/ocular surgery in the preceding 6 weeks,
pneumothorax in the preceding 6 weeks, haemoptysis of unknown origin, open pulmonary tuberculosis,
thoracic/abdominal/cerebral aneurysms, angiogram in
the previous 24 hours, recent pulmonary embolus and
others listed in the American Thoracic Society/European
Respiratory Society (ATS/ERS) guidelines46). Those
patients who have completed a pulmonary rehabilitation
programme in the previous 24 months are also excluded
from the study.
Allocation of participants
All participants recruited from a clinic receive the intervention or usual care depending on the allocation of the
clinic (ie, whether the clinic is allocated to ICG or UCG).
4

Early identification of COPD: case-finding and spirometry
Case-finding occurs in patients using the handheld COPD-6
device (Vitalograph, Ennis, Ireland). If COPD is suspected
during the initial testing (ie, forced expiratory volume in
1 second (FEV1)/forced expiratory volume in 6 seconds
(FEV6)<0.7522 47) or if the participant has difficulty using
the handheld device, spirometry is performed. Spirometry testing is performed by trained RAs using Easy on-PC
spirometers (ndd Medizintechnik AG, Zürich, Switzerland), following the ATS/ERS guidelines.46 Pre-bronchodilator and post-bronchodilator spirometry are performed
by participants at baseline. Readings are interpreted using
an algorithm. Participants with post-bronchodilator FEV1/
forced vital capacity (FVC) readings<0.7 are defined as
having COPD. Results are communicated to the participant’s clinic, where diagnosis is confirmed after taking
patient symptoms and risk factors into consideration.
Those with an existing diagnosis of COPD undergo testing
to confirm their diagnosis, where appropriate. If the participant already had spirometry in the previous 3 months, that
report is used for confirmation of diagnosis. Assistance
from respiratory scientists and/or respiratory physicians is
available for the interpretation of challenging reports.
Interdisciplinary care group
GPs and other clinic staff from the ICG who are involved
in the project are offered specific training. Training
Liang J, et al. BMJ Open 2017;7:e016985. doi:10.1136/bmjopen-2017-016985
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focuses on the COPD-X Plan for the management of
COPD, spirometry training and the ‘Supporting smoking
cessation: a guide for health professionals’.48
Participants in ICG clinics receive the RADICALS model
of care. The key components of RADICALS include intensive, individualised smoking cessation support from the
RA, home-based pulmonary rehabilitation from a specifically trained physiotherapist and a home medicines review
from a consultant pharmacist (accredited to undertake
medication reviews). The intervention is coordinated by
the RA at each site under the supervision of each participant’s GP and clinic staff. Participants are free to decline
or discontinue any or all of the intervention components
at any point in time; reasons for declining or discontinuing are obtained where possible. In addition, patients
with a diagnosis of COPD receive the LFA booklet ‘Better
Living with Chronic Obstructive Pulmonary Disease – A Patient
Guide’49 and management by their GP according to the
COPD-X Plan.
Smoking cessation support
Individualised smoking cessation support is coordinated
by the RA at each site and offered to participants who are
current smokers, regardless of COPD diagnosis. In ICG
clinics, the consultant pharmacist performing HMRs is
also involved in providing smoking cessation support for
smokers who have COPD. The intervention(s) offered will
be individually tailored to the patient’s smoking status,
needs and preferences. QUIT resources and a treatment
algorithm50 are used to guide treatment. Pharmacotherapy (over-the-counter and/or prescription) is recommended, if appropriate. If prescription medications are
required to assist smoking cessation, these are discussed
with the participant’s GP. Smoking cessation support is
offered at an initial consultation, with follow-up phone
calls at 1 week and 1 month from the initial consultation, as appropriate. Telephone follow-ups re-emphasise
the importance of quitting and long-term abstinence,
and also discuss issues surrounding relapse and relapse
prevention strategies.
Home-based pulmonary rehabilitation
A home-based pulmonary rehabilitation model is
employed,51 delivered by a specifically trained physiotherapist. The model includes one home visit with
weekly follow-up telephone calls using a motivational
interviewing approach to build confidence and set goals.
Home-based exercise training is prescribed based on each
patient’s exercise capacity. A goal for walking distance is
set and distance is recorded using a pedometer. Participants are encouraged to exercise for 30 min, five times
per week, and to record the completion of this activity in
a home diary. Resistance training for the arms and legs
uses daily activities and equipment that is readily available
in the home environment (eg, step-ups on an internal or
external step, sit to stand from a standard height chair,
water bottles for upper limb weights). Participants are
contacted by a physiotherapist each week by telephone for
Liang J, et al. BMJ Open 2017;7:e016985. doi:10.1136/bmjopen-2017-016985

7 weeks. During the weekly telephone calls, disease-specific self-management training and exercise progression
are achieved using the principles of motivational interviewing. Exercise goals and health goals are discussed and
documented each week in the home diary. The physiotherapist also refers to the LFA ‘Better Living with Chronic
Obstructive Pulmonary Disease – A Patient Guide’49 booklet
during discussions.
Home medicines review
A home medicines review52 from a consultant pharmacist
identifies any medication-related problems and deviations from COPD-X treatment guidelines. The consultant
pharmacist interviews participants at their homes and
assesses their medication use, including inhaler technique. Interventions for optimising medication adherence and inhaler use are also offered, if required. The
pharmacist generates a report for the GP, including
recommendations for optimising medication use and
adherence to COPD-X.
Usual care group
GPs in UCG practices continue to provide routine care
to their patients. GPs in these practices receive a copy of
the COPD-X Plan and the ‘Supporting Smoking Cessation: a
guide for health professionals’48 publication. Patient participants in UCG practices receive routine care from their
GP and Quitline referral, if appropriate. Those identified
to have COPD receive a copy of the LFA ‘Better Living with
Chronic Obstructive Pulmonary Disease – A Patient Guide’49
booklet.
Data collection and follow-up
Baseline data from each practice are collected at the
time of clinic enrolment. General information on practice staffing and specialist services provided (including
respiratory services provision) is obtained from the practice manager and/or practice staff using a standard data
collection form. Data collection from participants occurs
at baseline (time of recruitment) and at two follow-up
time points: 6 and 12 months from baseline. Baseline
data collection occurs through a face-to-face interview
with participants at the clinic of recruitment. Telephone,
mail or face-to-face follow-up is conducted to retain as
many participants in the trial as possible and reduce the
amount of missing data. Information on reason(s) for
withdrawal from the study are obtained where possible.
Patient demographics such as age, gender, nationality,
language, education, employment, marital status, income,
living arrangements, concession card status (ie, eligibility
for reduced out-of-pocket cost of healthcare services and
less expensive medicines) and healthcare visits in the
past 6 months are collected at baseline. Patients’ medical
records are reviewed to obtain medical and medication history. Smoking-related information is collected,
including smoking status, age at which smoking started,
smoking-related behaviours of participants and those
of friends and housemates, money spent on cigarettes,
5
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and information on previous smoking cessation attempts
and outcomes. Preferred methods of smoking cessation,
motivation and confidence to give up smoking are also
determined.
The Charlson Comorbidity Index is used to collect
information on comorbidities.53 Exhaled carbon
monoxide (CO) levels are measured using a handheld
piCO Smokerlyzer (Bedfont Scientific, Maidstone, Kent,
UK) to confirm self-report of abstinence. COPD-6 (Vitalograph, Ennis, Ireland) readings are obtained as part of
case-finding. Pre-bronchodilator and post-bronchodilator
spirometry are performed at baseline, and post-bronchodilator spirometry is performed in patients with COPD at
6-month and 12-month follow-ups.
The following data are collected from participants,
where appropriate, using validated tools at baseline, 6
and 12 months:
54
►► Heaviness of Smoking Index (HSI) : This is a
two-item scale measuring nicotine dependence based
on the number of cigarettes smoked per day and time
to first cigarette of the day. A score of 1–2 indicates
very low nicotine dependence and a score >5 indicates
high nicotine dependence.
55
►► Smoking Self-Efficacy Scale : This is a nine-item scale
that assesses confidence in the ability to abstain from
smoking in certain high-risk situations. A 5-point
scale ranging from ‘Not at all tempted’ to ‘Extremely
tempted’ is used to answer questions about temptation to smoke in various situations. A higher score
suggests greater temptation to smoke.
56 57
►► Readiness to Quit Ladder (adapted)
: This scale
has 10 response options that assess motivation to quit
smoking along a continuum. Responses range from
‘Not considering quitting in the near future’ to ‘Have
already quit smoking’. A higher score suggests greater
motivation to quit smoking.
58
►► Hospital Anxiety and Depression Scale (HADS) :
This is a 14-item questionnaire developed to screen
for the presence of anxiety and depression.
►► Visual Analogue Scales (VAS) for motivation and
confidence: 10-point scales are used to assess participants’ motivation and confidence to give up smoking.
Data collected from participants identified to have
COPD using validated tools at baseline, 6 and 12 months
include:
59
►► SGRQ : This is a 50-item questionnaire developed
to measure health status (quality of life) in patients
with diseases of airways obstruction. Questions are
answered on three domains: symptoms (frequency
and severity), activities that cause or are limited by
breathlessness, and impact (on social functioning,
psychological disturbances). Scores range from 0 to
100, with higher scores indicating worse HRQoL.
60
►► COPD Assessment Test (CAT) : This is an eightitem questionnaire used to measure the health
status of patients with COPD. Each item is formatted
as a semantic 6-point differential scale (0–5) with
contrasting adjectives. All items can be scored as a
6

single scale ranging from 0 to 40. Higher scores indicate worse health.
►► Modified Medical Research Council (mMRC) Dyspnoea Scale61 62: This is a scale consisting of five statements describing levels of dyspnoea based on the
extent to which various physical activities precipitate breathlessness. Each statement corresponds to
a grade; grade 0 indicates no dyspnoea and grade
4 indicates severe dyspnoea to the point of almost
incapacity.
63
►► EQ-5D : This is a generic instrument used as a
measure of health outcome. This instrument obtains
information across the five dimensions of mobility,
self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension is scored on a
5-point Likert scale (no problems/slight problems/
moderate problems/severe problems/extreme problems). The EQ-VAS, a visual analogue scale contained
within the EQ-5D questionnaire for recording an individual’s rating of their current HRQoL state, is also
administered.
64
►► Beliefs and Behaviour Questionnaire (BBQ) : This
30-item questionnaire measures beliefs, experiences
and adherent behaviour on 5-point Likert scales.
Medication adherence will be assessed using the
TABS (Tool for Adherence Behaviour and Screening)
questionnaire, a subscale within the BBQ.
Participants who receive the HMR are asked to complete
an anonymous satisfaction questionnaire, adapted from
surveys used in previous studies.65–68 GP feedback on
each HMR conducted is also sought by asking them to
complete a questionnaire when they receive the report
from the consultant pharmacist.
Data from participants will be stored in locked filing
cabinets at the practices or at Monash University.
Collected data will be de-identified, entered into an
electronic database and saved on a password-protected
computer. Data will be stored under these conditions
for the duration of the trial and for the required time
period after trial end, as stipulated by the Monash
University regulations. Only investigators and research
staff involved in the trial will have access to participant
data. An independent data and safety monitoring board
(DSMB) has been set up comprising a respiratory consultant with experience in development of clinical guidelines for management of COPD and clinical research; a
physiotherapist with expertise in translation of research
evidence into clinical practice, especially pulmonary
rehabilitation; and a GP with experience in conducting
clinical studies in primary care and reviewing the
evidence base for treatment in respiratory diseases. The
DSMB will meet periodically and as required to evaluate
study progress, including patient accrual and retention,
and review cumulative study data to evaluate safety, study
conduct, and scientific validity and integrity of the trial.
The DSMB will also provide independent advice to the
investigators whether the study should continue without
change, be modified or terminated.
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Blinding
All outcome measure assessments are conducted by RAs
blinded to treatment allocation. All possible measures are
taken to prevent revealing treatment allocation to RAs
conducting these assessments.
Primary endpoint
The primary endpoint is change in HRQoL, as measured
by the SGRQ, at 6 months from baseline. The SGRQ
is extensively used in interventional studies involving
patients with all COPD severities. The use of the SGRQ
enables capturing of HRQoL effects of the RADICALS
intervention across the spectrum of COPD severity.
Secondary endpoints
Secondary outcomes of the trial are:
►► exhaled CO-verified 7-day point prevalence abstinence in smokers at 6 and 12 months from baseline;
a participant with an exhaled CO level <7 parts per
million (ppm)will be considered abstinent
►► change in lung function (FEV1) in patients with COPD
at 6 and 12 months from baseline
►► change in SGRQ score in patients with COPD at 12
months from baseline
►► change in CAT score in patients with COPD at 6 and
12 months from baseline
►► change in response to EQ-5D in patients with COPD
at 6 and 12 months from baseline
►► change in dyspnoea (mMRC score) in patients with
COPD at 6 and 12 months from baseline
►► change in HSI score of smokers at 6 and 12 months
from baseline
►► change in frequency of emergency department presentations or hospitalisations in patients with COPD at
6 and 12 months from baseline
►► change in frequency of COPD-related unplanned GP
visits in patients with COPD at 6 and 12 months from
baseline
►► change in anxiety and depression scores on the HADS
in patients with COPD at 6 and 12 months from
baseline
►► change in medication adherence as measured by the
TABS questionnaire in patients with COPD at 6 and
12 months from baseline
►► proportion of smokers with spirometry-confirmed
COPD at baseline
►► patient satisfaction with the home medicines review
and GP feedback on home medicines review based on
completion of standard surveys.
Sample size
Change in SGRQ score at 6 months from enrolment is the
primary efficacy endpoint. A difference of at least four
points between treatment arms is considered clinically
significant.59 Assuming a conservative SD of 10 points,59
99 participants per group (80% power and p=0.05) will
be required. Adjusting for clustering by practice (intraclass correlation=0.0169 and cluster size 10), the required
Liang J, et al. BMJ Open 2017;7:e016985. doi:10.1136/bmjopen-2017-016985

sample is 108 per arm. To allow for 20% attrition after
enrolment, recruitment will continue until 280 (140 in
each arm) participants are enrolled in the trial. Therefore, at least 28 primary care practices need to be recruited
and 14 each randomised to ICG and UCG. From each
practice, 50 smokers will be screened to identify 10 with
COPD (post-bronchodilator FEV1/FVC<0.7).70 A sample
of 1400 smokers would allow the proportion of patients
with COPD to be estimated within ±2% (approximately),
with a 95% CI from 18% to 22%. Recruitment of 700
smokers in each arm would allow a difference of 6% in
abstinence rates to be detected (eg, 12% in control vs
18% in intervention) with 86% power at the 5% level of
significance.
Statistical analysis
Baseline demographic and clinical characteristics will
be summarised using proportions, means and SD, or
medians and IQRs, as appropriate. Changes in study variables within the intervention and control practices will be
examined and any differences in outcomes between the
two groups will be compared. Unadjusted and adjusted
analyses will be performed with analysis by COPD status
(existing or no existing COPD diagnosis) as a covariate
and an interaction of the intervention with this covariate.
The mean change in SGRQ scores at 6 months in each
treatment group will be estimated. Differences between
groups and 95% CIs will be determined. Multivariable
analyses will be performed using multiple linear regression for continuous outcomes and multiple logistic regression for binary outcomes. All regression analyses will be
adjusted for clustering, prognostic variables and potential
confounders. Data will be analysed using the intention-totreat principle. Sensitivity analyses using multiple imputation methods may be performed to account for missing
data. Sensitivity analysis using different exhaled CO
cut-off values (3-10ppm) will be performed. Participants
who are lost to follow-up will be regarded as smokers (ie,
deemed to have relapsed smoking at that point). Per-protocol analysis will also be undertaken.
Economic evaluation
Economic evaluation of health interventions is important
in aiding decision-making processes, especially in matters
of government reimbursement.71 Various costing information will be collected as part of the trial. Direct costs
of the intervention will include staff time, consumables, communications, overheads and staff transportation. Information on the cost of the intervention will
be collected by staff within the trial. Medicare Benefits
Scheme and Pharmaceutical Benefits Scheme data may
also be used to assign costs to intervention components.
Data on the use of health services including GP, specialist
and emergency department visits, and hospitalisations
will be collected from patients, and the associated costs
with the use of these will be considered for evaluation.
The EQ-5D will be used to classify health states
and determine an individual’s utility of health state.
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Quality-adjusted life years (QALYs), which can capture
the impact on both quantity and quality of life (ie,
mortality and morbidity),72 will be generated using utility
weights outlined in previous literature.71 An incremental
cost-effectiveness ratio will be used to compare the differences in costs and differences in gains in QALYs between
the intervention and usual care. Other outcomes considered for economic analysis may include change in SGRQ
scores and change in number of individuals abstaining
from smoking.
Trial status
The trial is in the recruitment phase at the time of manuscript submission.
The first participant was enrolled on 5 March 2015.
End of data collection is expected in April 2018.

Discussion
Diagnosis and management of COPD are suboptimal
in Australian primary care despite the availability of
evidence-based treatment guidelines. Effective interventions are required for case-finding and diagnosis of
COPD, maintaining and improving HRQoL, promoting
self-management and improving participation in exercise
programmes. Studies involving multidisciplinary, integrated care models have signposted various issues that
should be addressed in future studies for better COPD
management. These include better patient involvement,
more individualised and intensive smoking cessation
interventions, new ways of delivering pulmonary rehabilitation, and prompt intervention following COPD
diagnosis.24 40 42 The RADICALS model of care aims to
address these aspects. The model emphasises an interdisciplinary approach to COPD management by providing
patient-centred care through collaborative working relationships between GPs, nursing staff, other practice staff,
pharmacists, physiotherapists and respiratory physicians/
scientists. Individualised smoking cessation support,
HMRs, home-based pulmonary rehabilitation and interdisciplinary care are the key components of RADICALS.
HMRs can identify existing medication-related problems and make recommendations regarding COPD and
smoking cessation therapy. Medication reviews have the
potential to improve adherence to evidence-based pharmacological treatments for COPD. A home-based pulmonary rehabilitation programme is known to be as effective
as centre-based pulmonary rehabilitation.51 Home-based
pulmonary rehabilitation may overcome some of the
barriers associated with centre-based rehabilitation, such
as inconvenience of travel and long waiting periods.
The proposed RADICALS model has the potential to
reduce the burden and morbidity associated with smoking
and COPD, and improve HRQoL for affected patients. If
the intervention is successful, the RADICALS programme
could potentially be integrated into general practices across
Australia and sustained over time. Resources and services
already exist in the Australian community that would aid its
8

implementation. It should be noted that the HMR service
and the home-based pulmonary rehabilitation programme
offered as part of RADICALS are funded solely through the
trial, and not through the MBS. Outcomes of this study may
inform integration of this service model into primary care,
including service payments through the MBS. Our casefinding methods are informed by a previous COPD casefinding study conducted in Australian primary care,47 and
the LFA recommendations for case-finding based on FEV1/
FEV6 readings,22 potentially adding to the evidence base in
this area.
Our study is a large implementation trial in primary care
involving current smokers, ex-smokers and patients with
an existing diagnosis of COPD. Some strengths include
the cluster randomisation of general practices, which minimises the risk of contamination, and outcome assessment
by staff blinded to treatment allocation. Due to the nature
of the intervention, blinding of participants and health
professionals is not possible, introducing the potential for
Hawthorne effect. The RADICALS intervention is primarily
designed for Australian primary care based on the COPD-X
guidelines, which do not use the GOLD ABCD grading
system for symptoms, potentially limiting extrapolation of
our findings to studies using the ABCD grading. Nevertheless, we use the mMRC Dyspnoea Scale and the CAT for
symptom assessment in participants, allowing us to carry out
subgroup analyses, if required. Moreover, the ABCD assessment tool performed no better than the spirometric grades
for mortality prediction or other important health outcomes
in COPD.73–75 Using an FEV1/FEV6 cut-off of 0.75 may result
in over-referral of participants for spirometry; however, local
guideline recommendations have been followed.
Follow-up method for participants may differ
depending on participant availability/preference, potentially introducing detection and/or response bias. Sensitivity analyses will be performed where possible to identify
any effects of follow-up method on outcomes.

Ethics and dissemination
Any proposed modifications to the protocol will be
approved by the investigator team, before being communicated to relevant parties.
Dissemination
Results of the trial will be submitted to peer-reviewed
journals, and presented at both national and international research conferences, where possible.
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